Cardiovascular Surgery Department, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan PRC.
Clinical Research Center, Southwest Medical University, Luzhou, Sichuan PRC.
Int J Biol Sci. 2022 Jan 1;18(3):923-941. doi: 10.7150/ijbs.63819. eCollection 2022.
Atherosclerosis is the principal cause of cardiovascular diseases (CVDs) which are the major cause of death worldwide. Mechanical force plays an essential role in cardiovascular health and disease. To bring the awareness of mechanosensitive Piezo1 role in atherosclerosis and its therapeutic potentials we review recent literature to highlight its involvement in various mechanisms of the disease. Recent studies reported Piezo1 channel as a sensor, and transducer of various mechanical forces into biochemical signals, which affect various cellular activities such as proliferation, migration, apoptosis and vascular remodeling including immune/inflammatory mechanisms fundamental phenomenon in atherogenesis. Numerous evidences suggest Piezo1 as a player in different mechanisms of cell biology, including immune/inflammatory and other cellular mechanisms correlated with atherosclerosis. This review discusses mechanistic insight about this matter and highlights the drugability and therapeutic potentials consistent with emerging functions Piezo1 in various mechanisms of atherosclerosis. Based on the recent works, we suggest Piezo1 as potential therapeutic target and a valid candidate for future research. Therefore, a deeper exploration of Piezo1 biology and translation towards the clinic will be a novel strategy for treating atherosclerosis and other CVDs.
动脉粥样硬化是心血管疾病(CVDs)的主要病因,CVDs 是全球主要的死亡原因。机械力在心血管健康和疾病中起着至关重要的作用。为了提高对机械敏感 Piezo1 在动脉粥样硬化及其治疗潜力中的作用的认识,我们回顾了最近的文献,强调了其在疾病的各种机制中的参与。最近的研究报告 Piezo1 通道作为各种机械力转化为生化信号的传感器和转换器,这些信号影响各种细胞活动,如增殖、迁移、凋亡和血管重塑,包括免疫/炎症机制,这是动脉粥样硬化形成的基本现象。大量证据表明 Piezo1 是细胞生物学不同机制中的一个参与者,包括免疫/炎症和与动脉粥样硬化相关的其他细胞机制。这篇综述讨论了这方面的机制见解,并强调了与动脉粥样硬化的各种机制一致的药物治疗潜力和治疗潜力。基于最近的研究工作,我们提出 Piezo1 作为潜在的治疗靶点,是未来研究的一个有价值的候选者。因此,深入探索 Piezo1 生物学并将其转化为临床应用将是治疗动脉粥样硬化和其他 CVDs 的一种新策略。